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Abstract 
Background: Parasite prevalence has been used widely as a measure of malaria transmission, especially in malaria 
endemic areas. However, its contribution and relationship to malaria mortality across different age groups has not 
been well investigated. Previous studies in a health and demographic surveillance systems (HDSS) platform in western 
Kenya quantified the contribution of incidence and entomological inoculation rates (EIR) to mortality. The study 
assessed the relationship between outcomes of malaria parasitaemia surveys and mortality across age groups.
Methods: Parasitological data from annual cross-sectional surveys from the Kisumu HDSS between 2007 and 2015 
were used to determine malaria parasite prevalence (PP) and clinical malaria (parasites plus reported fever within 24 h 
or temperature above 37.5 °C). Household surveys and verbal autopsy (VA) were used to obtain data on all-cause 
and malaria-specific mortality. Bayesian negative binomial geo-statistical regression models were used to investigate 
the association of PP/clinical malaria with mortality across different age groups. Estimates based on yearly data were 
compared with those from aggregated data over 4 to 5-year periods, which is the typical period that mortality data 
are available from national demographic and health surveys.
Results: Using 5-year aggregated data, associations were established between parasite prevalence and malaria-
specific mortality in the whole population  (RRmalaria = 1.66; 95% Bayesian Credible Intervals: 1.07–2.54) and chil-
dren 1–4 years  (RRmalaria = 2.29; 1.17–4.29). While clinical malaria was associated with both all-cause and malaria-
specific mortality in combined ages  (RRall-cause = 1.32; 1.01–1.74);  (RRmalaria = 2.50; 1.27–4.81), children 1–4 years 
 (RRall-cause = 1.89; 1.00–3.51);  (RRmalaria = 3.37; 1.23–8.93) and in older children 5–14 years  (RRall-cause = 3.94; 1.34–11.10); 
 (RRmalaria = 7.56; 1.20–39.54), no association was found among neonates, adults (15–59 years) and the elderly (60+ 
years). Distance to health facilities, socioeconomic status, elevation and survey year were important factors for all-
cause and malaria-specific mortality.
Conclusion: Malaria parasitaemia from cross-sectional surveys was associated with mortality across age groups over 
4 to 5 year periods with clinical malaria more strongly associated with mortality than parasite prevalence. This effect 
was stronger in children 5–14 years compared to other age-groups. Further analyses of data from other HDSS sites 
or similar platforms would be useful in investigating the relationship between malaria and mortality across different 
endemicity levels.
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Background
There has been a substantial reduction in malaria related 
mortality worldwide over the last decade, however, the 
burden is still disproportionately felt in sub-Saharan 
Africa (SSA) [1]. Due to the high burden in children 
and pregnant women [2], malaria control intervention 
resources in previous years have been targeted to these 
vulnerable populations. Increased quality data on malaria 
infection dynamics and mortality across all ages [3] has 
created an increased awareness of the burden of disease 
amongst the other populations, and policies have been 
expanded to ensure universal coverage with effective vec-
tor control methods (e.g. long-lasting insecticidal nets 
[LLIN]), availability of diagnostics (e.g. rapid diagnostic 
tests, RDT), and availability of appropriate treatments 
(e.g. artemisinin-based combination therapy, ACT) to all.
There is evidence that the malaria burden in older chil-
dren and adults in terms of mortality and parasite preva-
lence [4–6] is higher than had been thought of previously. 
With data analysed from a health and demographic sur-
veillance system (HDSS) in western Kenya run by the 
Kenya Medical Research Institute (KEMRI) and Cent-
ers for Disease Control and Prevention (CDC) showing 
that, largely due to increased malaria/HIV prevention 
and treatment interventions, malaria mortality rates 
decreased in young children and persons aged ≥ 15 years, 
but remained stable in 5–14 year olds [6]; suggesting that 
malaria control efforts should be intensified in this group. 
Furthermore, older children and adults have been shown 
to act as reservoirs of transmission due to high levels of 
asymptomatic infections [7], supporting the current pol-
icy of universal coverage of malaria control interventions.
Measuring malaria transmission intensity and its effect 
on mortality can be used to monitor disease burden 
and assess the impact of interventions and control pro-
grammes. This has been done previously using entomo-
logical inoculation rates (EIR) [8, 9]; however, measuring 
EIR is expensive, time consuming and is often imprecise, 
particularly in low transmission settings. Other meas-
ures of malaria transmission include slide positivity rate 
(SPR), parasite prevalence, disease incidence, sporozoite 
rate, and vectorial capacity [10–13].
Malaria parasite prevalence (PP) surveys carried out 
mostly during peak transmission times through repre-
sentative sampling of populations are a preferred method 
for measuring malaria burden because reporting from 
weak or non-existent health systems is inadequate to 
measure incidence [14], at the same time health facilities 
do not capture asymptomatic infections which are impor-
tant for malaria transmission. Furthermore, PP survey 
data are easier to interpret and less prone to uncertainty 
compared to other measures [15]. These surveys are how-
ever limited in their ability to capture malaria morbidity, 
seasonality of transmission and monitor temporal trends 
from surveys that are not seasonally aligned [16]. With 
regular, consistent survey intervals, stringent methodol-
ogy in sampling and diagnosis, PP surveys can provide 
measures of malaria transmission which are useful to 
policy makers.
Due to their nature, HDSS sites can be used to col-
lect data that are well aligned in space and time, so as 
to investigate variations in malaria transmission in rela-
tion to morbidity and mortality. They provide data on 
mortality across age groups, and in conjunction with 
PP surveys, offer a unique platform through which the 
relationship between malaria transmission and mortal-
ity can be investigated while taking into consideration 
spatio-temporal factors [16–18] and hence monitor the 
impact of interventions over time. One such project, the 
Malaria Transmission Intensity and Mortality Burden 
across Africa (MTIMBA) investigated the effect of EIR as 
a measure of exposure and its effect on mortality in sev-
eral HDSS sites in Africa and showed that small changes 
in transmission dynamics as measured by EIR, impact 
greatly on mortality [8, 9].
This study sought to understand how malaria para-
site prevalence and clinical malaria translate into mor-
tality and consequently help inform national control 
programmes on how to best use their survey data in esti-
mating mortality. The relation between malaria preva-
lence and mortality was explored across all age-groups 
using Bayesian geostatistical models on data collected 
between 2007 and 2015 from the KEMRI and CDC 
HDSS (KHDSS) site in western Kenya. There have been 
no studies done to investigate the usefulness of PP and 
its association with mortality using data that are well 
aligned in space and time across different age groups 
in similar settings; hence enriching the knowledge of 
malaria transmission-mortality using high quality con-
sistent data. Since estimation of malaria deaths is still not 
very clear, results of this study would clarify the poten-
tials of PP surveys to reliably estimate malaria deaths and 
as its intensity reduces worldwide, help inform decisions 
on resource allocation and monitoring the impact of 
interventions.
Methods
Study area and population
The KHDSS located in Siaya County of western Kenya 
follows a population of over 240,000 people as of mid-
2015 in an area of over 700  km2 [19]. This HDSS is 
located in a malaria endemic zone with a high burden of 
HIV/AIDS compared to the rest of the country [20, 21].
From the HDSS, data on an initial population at base-
line was collected followed by subsequent 4 monthly 
cycles every year during which data were collected on 
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births, deaths, in-migration and out-migrations. These 
data were used to estimate person-years of observation 
(pyo) that served as a denominator to calculate mortal-
ity rates. Verbal autopsy (VA) was used to determine 
malaria-specific mortality rates. The methods used for 
verbal autopsy have been described in detail elsewhere 
[19, 22]; it involves capturing data on a deceased person’s 
last illness, signs, symptoms and medical history which is 
then used to determine the most probable cause of death 
using a computer-based Bayesian expert algorithm called 
InterVA [23].
Malaria prevalence
Annual all-age malaria and anaemia prevalence sur-
veys were conducted by randomly sampling compounds 
within the HDSS, and testing all consenting members of 
the compound for malaria by blood smear microscopy, 
from the population during the peak malaria transmis-
sion period in July. Details of the sampling by year are 
shown in Additional file  1. Trained interviewers then 
visited the compounds, administered a questionnaire 
to collect information on demographics, risk factors for 
malaria infection, healthcare-seeking, previous illness, 
socioeconomic status, LLIN ownership/use, and col-
lected a blood sample to prepare thick and thin smears 
for microscopy. The blood slides were transported to a 
central laboratory, stained with 10% Giemsa and exam-
ined for malaria parasites by expert microscopists.
Two measures of transmission were considered; preva-
lence of malaria parasites and clinical malaria for com-
parative purposes. Parasite prevalence by age group, 
village, and year was defined as the proportion of par-
ticipants in each village that had malaria by microscopy 
out of all the participants from the same village who were 
tested for malaria. Similarly, clinical malaria prevalence 
was defined as the proportion of participants in each vil-
lage who had malaria parasites of any density by micros-
copy in combination with either a reported fever in the 
previous 24 h or a temperature of 37.5 °C and above out 
of all those tested.
Data management and statistical analysis
Rates of clinical malaria and PP were aggregated at village 
level and linked to mortality data by village, year of study 
and age group. The age groups were defined as: 0–28 days 
(neonates), 1–11  months (infants), 1–4  years (child), 
5–14 years (older child), 15–59 (adults) and 60+ (elderly). 
Crude and age specific all-cause/malaria-specific mortal-
ity rates were calculated by dividing the deaths in each 
group with the total person-years observed (pyo) in that 
group.
A measure of socioeconomic status was constructed 
based on household asset ownership using a composite 
score, derived from multiple correspondence analysis 
(MCA) [24] and categorized into 3 levels as least poor 
for the well off, poor for the average and poorest for 
the lowest rank while LLIN coverage was calculated 
as the percentage of households in a village owning at 
least one net per two people in a given year. Distance 
to health facilities was calculated as the networked 
distance of each household from the nearest health 
facility, and classified into 3 categories as less than 
1  km, 1 to 2  km and greater than 2  km. the elevation 
of each household was downloaded from the remote 
sensing United States geological survey (USGS) Earth 
Resources Observation and Science (EROS) website 
[25]. These variables were also aggregated at village 
level and linked to the parasitaemia and mortality data.
The analysis considered two approaches; in one 
approach, the data were aggregated on a yearly basis, 
hence 9 years of observation; the second approach was 
aggregating the data into two periods (2007–2010 and 
2011–2015).
For each age group, Bayesian negative binomial geo-
statistical models were fitted to assess the relationship 
between PP and all-cause/malaria-specific mortality. 
Variable selection based on bivariate negative binomial 
models was used to identify potential confounders. 
Variables with a p-value below 0.1 were included in the 
final geostatistical models so as not leave out important 
variable whose effects would be missed when investi-
gated alone, but become important if included in com-
bination with other factors. Spatial correlation was 
taken into account by village specific random effects 
modelled via a Gaussian process with a mean of zero 
and an exponential correlation matrix of the distance 
between villages in the study [26]. Bayesian models 
were fitted in OpenBugs version 3.1.2 (Imperial Col-
lege and Medical Research Council London, UK) using 
Markov Chain Monte Carlo (MCMC) simulation for 
parameter estimation. Regression coefficients from the 
Bayesian geostatistical model were exponentiated to 
obtain prevalence rate ratios (PRR) and summarized 
by their posterior median and 95% Bayesian Credible 
Intervals (BCI). Covariate effects were considered sta-
tistically important when the BCI of the corresponding 
regression coefficients on the log scale did not include 
zero. Due to the nature of Bayesian statistical inference, 
the terminology of statistically significant was replaced 
by statistically important effect when reporting results. 
In this paper, the results for the association between 
clinical malaria and all-cause mortality are presented; 
clinical malaria and malaria-specific mortality; and 
lastly PP and both all-cause/malaria-specific mortality 
in that order. Model formulation details are provided in 
Additional file 2.
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Results
Descriptive statistics
Between the year 2007 and 2015, over 441,000 individu-
als were enrolled/monitored in the HDSS contributing a 
total of 2,114,223 pyo and 26,283 deaths, for an average 
crude death rate of 12.4 (95% confidence interval; 12.3–
12.6) deaths per 1000 pyo as shown in Table 1.
All-cause mortality during the study period rose from 
15.5 (14.9–16.1) deaths per 1000 pyo in 2007 to 18.8 
(18.2–19.3) in 2008 then dropped to a low of 9.4 (9.0–9.8) 
in the year 2015 with malaria-specific mortality following 
a similar trend; rising from 1.3 (1.2–1.5) deaths per 1000 
pyo in 2007 to a high of 3.5 (3.3–3.7) in 2008, but eventu-
ally dropping to 0.9 (0.7–1.0) deaths per 1000 pyo in 2015 
(Table 1). The average PP during the whole study period 
was 35.8% (35.2–36.5); ranging between 27.3% in 2008 to 
a high of 39.7% in 2010 but then dropped over the years 
to 29.8% in 2015. A further breakdown of the positive 
slides showed that 8.1% (7.7–10.4) of the respondents 
had clinical malaria (parasites and fever); on average one 
fifth of all the positives had clinical malaria (Fig. 1).
The highest parasite prevalence was observed among 
older children aged 5–14  years, with an average PP of 
56% (95% CI 54–57), followed by children aged 1–4 years 
at 40% (39–41), adults at 22% (21–24), and infants at 22% 
(19–25); the elderly at 14% (12–16) had the lowest rate. 
The age distribution of prevalence indicates an increase 
in parasite prevalence from infanthood to older children 
followed by a drop as the population ages (Fig. 2a). How-
ever, by including the presence of fever, a rise in clinical 
malaria from infants to children aged 1 to 4  years was 
observed, after which it drops in the 5–14 age-group and 
in adults but rises slightly among the elderly. The highest 
prevalence of clinical malaria was in infants with a peak 
of 18.4% among those tested in the year 2007 (Fig. 2b).
Model‑based results
Relationship between clinical malaria and all‑cause mortality
The following variables met the criteria for inclusion in 
the age-specific geostatistical mortality models: reported 
net usage, distance to health facilities, socioeconomic 
status, year of study and altitude. For comparability, these 
variables were included in the Bayesian models fitted by 
age group. Results in Table  2 show that the prevalence 
of confirmed malaria when aggregated over four and 
5-year periods, was associated with all-cause mortality 
in the combined age groups (RR = 1.32; 95% BCI: 1.01–
1.74), in the 1–4 year olds (RR = 1.89; 1.00–3.51) and in 
the 5–14  year olds (RR = 3.94; 1.34–11.1). Increase in 
distance to health facilities was associated with higher 
mortality among neonates, children aged 1–4 years and 
the combined age group analysis. Risk of all-cause mor-
tality was higher in the period 2007–2010 compared to 
2011–2015 in all ages except in neonates. Higher SES 
and increased elevation were both associated with lower 
mortality. The association between reported net use and 
mortality was not statistically important across most 
age groups save for the elderly. The minimum distance 
at which spatial correlation was below 5% ranged from 
13.2  km to 50  km for all the age groups. The analyses 
of the yearly prevalence data did not show a statistically 
important relation between confirmed malaria and all-
cause mortality (see Additional file 3).
Relationship between clinical malaria and malaria‑specific 
mortality
The pattern of association between clinical malaria and 
malaria-specific mortality across all age groups was 
similar to that of clinical malaria and all-cause mortal-
ity, however, the magnitude of the estimates was higher. 
The effect of clinical malaria risk on malaria-specific 
Table 1 All-cause/malaria specific mortality, clinical malaria and malaria parasite prevalence by year
pyo person years of observation
Year Person years 
of observation
Sampled 
population
Malaria parasite 
prevalence
Clinical malaria 
prevalence
All‑cause mortality rate 
per 1000 pyo
Malaria‑specific 
mortality rate 
per 1000 pyo
2007 181,537 1270 29.6% (27.1–32.2) 7.2% (5.8–8.7) 15.5 (14.9–16.1) 1.3 (1.2–1.5)
2008 230,374 1039 27.3% (24.6–30.2) 6.0% (4.6–7.6) 18.8 (18.2–19.3) 3.5 (3.3–3.7)
2009 230,373 2508 39.0% (37.1–40.9) 7.5% (6.5–8.6) 15.6 (15.1–16.2) 2.9 (2.6–3.1)
2010 233,871 5243 39.7% (38.4–41.0) 7.9% (7.2–8.6) 12.4 (11.9–12.8) 2.1 (1.9–2.3)
2011 238,524 2091 39.2% (37.1–41.3) 8.5% (7.3–9.7) 10.9 (10.5–11.3) 1.4 (1.2–1.5)
2012 246,254 2719 34.1% (32.3–35.9) 7.8% (6.8–8.8) 10.2 (9.8–10.6) 1.4 (1.2–1.5)
2013 249,757 2358 34.5% (32.6–36.5) 10.5% (9.3–11.8) 10.5 (10.1–10.9) 1.6 (1.4–1.7)
2014 252,173 1934 35.6% (33.4–37.8) 8.4% (7.2–9.7) 10.2 (9.8–10.6) 1.0 (0.9–1.2)
2015 251,360 1756 29.8% (27.7–32.0) 7.5% (6.2–9.1) 9.4 (9.0–9.8) 0.9 (0.7–1.0)
Overall 2,114,223 20,918 35.8% (35.2–36.5) 8.1% (7.7–8.4) 12.4 (12.3–12.6) 1.8 (1.7–1.9)
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mortality was statistically important and strong among 
children 5–14 years (RR = 7.56; 1.20–39.54) and 1–4 year 
olds (RR = 3.37; 1.23–8.93). Meanwhile in the overall 
population, malaria-mortality rate increases two and 
half times for every increase in the proportion of clinical 
malaria by 1% (RR = 2.50; 1.27–4.81) as shown in Table 3. 
Similar to all-cause mortality analysis, statistically impor-
tant variables were elevation, distance to health facilities, 
year of study and socioeconomic status. Reported net use 
was not statistically important for malaria-specific mor-
tality in any ages except among the elderly (RR = 2.05; 
1.04–4.34) in the yearly analysis, where an elevated risk 
with higher levels of net use was observed. The minimum 
distance at which spatial correlation was not impor-
tant (< 5%) ranged from 13.4 to 50.42  km. The analyses 
of the yearly aggregated data did not show a statistically 
important relation between confirmed malaria risk and 
malaria-specific mortality (see Additional file 4).
Relationship between parasite prevalence and all‑cause/
malaria specific mortality
The relation between PP and all-cause mortality was not 
statistically important across all ages (Table 2). However, 
there was a statistically important association between 
PP and malaria-specific mortality (Table  3) among 
children aged 1–4 years (RR = 2.29; 95% BCI: 1.17–4.29), 
and in the combined age group (RR = 1.66; 95% BCI: 
1.07–2.54) when data was aggregated over 5 to 4  year. 
Analyses of yearly data did not reveal statistically impor-
tant associations except between PP and all-cause mor-
tality among the adults (RR = 1.23; 95% BCI: 1.01–1.50) 
(see Additional file 3) and with malaria-specific mortal-
ity among the elderly (RR = 3.42; 95% CI: 1.39–8.63) (see 
Additional file 4).
Discussion
Using data from community level cross-sectional sur-
veys, it was shown that; parasite prevalence is associ-
ated with malaria-mortality in the overall population, 
while clinical malaria is associated with both all-cause 
and malaria-specific mortality more so in the age groups 
1–4  years and 5–14  years. This relationship was estab-
lished by fitting over 50 different Bayesian geo-statistical 
models across different age groups on large data from 
verbal autopsies, longitudinal household surveys, and 
cross-sectional malaria parasitaemia surveys carried out 
annually over 9  years in the HDSS located in a malaria 
endemic region of western Kenya. These data aggregated 
over four to 5-year periods showed statistically impor-
tant relations between clinical malaria and mortality 
Fig. 1 All-cause and malaria specific mortality rates versus malaria parasite and clinical malaria prevalence
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Fig. 2 Malaria parasite prevalence (a) and clinical malaria (b) by age groups
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(all-cause and malaria-specific) in the overall popula-
tion, in children 1–4, and older children aged 5–14 years 
old, while PP had a statistically important association 
with malaria-specific mortality in 1–4  year olds and in 
the overall population. Meanwhile, analyses of the same 
data, annually aggregated did not establish any associa-
tion between prevalence of clinical malaria nor PP with 
either all-cause or malaria-specific mortality across most 
age groups except for all-cause mortality in adults aged 
15–59 years and malaria-specific mortality in the elderly.
Studies in malaria-endemic areas have also shown that 
children above the age of 5  years are least affected by 
the malaria burden in terms of confirmed symptomatic 
malaria and mortality compared to other age groups, 
even though they remain the biggest reservoir of the 
malaria parasites [5, 27]. However, the long-term effects 
of declining transmission on mortality in this age group 
have not been well explored. This study showed a seven-
fold increase in malaria-specific mortality for every 1% 
increase in clinical malaria prevalence, which was more 
than twice the effect in children 1–4 year old. This find-
ing could be attributed to low utilization of ITNs by older 
children compared to other age groups in this study, as 
well as from previous studies [6] as well as poor health 
care-seeking behaviour among the same age group [28], 
resulting in higher mortality rates when data is captured 
at household level compared to sentinel health facilities. 
This reinforces the importance of universal coverage of 
malaria control interventions particularly in high trans-
mission areas.
The absence of an association between PP and all-
cause mortality could be due to several factors. First, 
parasite prevalence from the community might capture 
more asymptomatic carriers who have acquired immu-
nity from malaria disease, eventually recover without 
adverse outcomes and hence survive. Second, malaria 
mortality is usually preceded by severe illness and, 
therefore, the PP data may be biased, as most of those 
Table 3 Posterior estimates for the effects of prevalence (PP and confirmed malaria) on malaria-specific mortality
Mortality and malaria data aggregated by 4 to 5-year periods (i.e. 2007–2010 and 2011–2015)
a The effects are presented as the median of mortality rate ratios (RR) and 95% Bayesian Credible Intervals (BCI) adjusted for geographical variation and other 
predictors
b Age-adjusted
c They are obtained from different models. Estimates of the rest of the predictors are from the models with confirmed malaria and do not differ from the PP model. PP 
estimates are only provided for comparison purposes
d Minimum distance in kilometres at which spatial correlation is less than 5%
Covariate Infants 1–4 years 5–14 years 15–59 years 60+ Overallb
RR (95%  BCIa) RR (95% BCI) RR (95% BCI) RR (95% BCI) RR (95% BCI) RR (95% BCI)
PPc 1.73 (0.74–4.21) 2.29 (1.17–4.29) 0.56 (0.14–2.03) 1.55 (0.48–4.86) 2.24 (0.67–7.44) 1.66 (1.07–2.54)
Clinical  malariac 2.23 (0.55–8.36) 3.37 (1.23–8.93) 7.56 (1.20–39.54) 0.60 (0.08–3.91) 0.77 (0.09–5.64) 2.50 (1.27–4.81)
Net use 1.11 (0.61–1.97) 0.74 (0.48–1.14) 1.02 (0.40–2.35) 0.64 (0.28–1.35) 0.72 (0.30–1.77) 0.81 (0.61–1.11)
Distance to facility
 0–1 km 1 1 1 1 1 1
 1–2 km 1.11 (0.85–1.48) 0.89 (0.72–1.11) 1.17 (0.75–1.86) 1.36 (0.93–2.03) 1.10 (0.71–1.72) 1.02 (0.89–1.17)
 > 2 km 1.19 (0.88–1.61) 1.00 (0.80–1.27) 1.56 (0.97–2.52) 1.13 (0.73–1.76) 1.15 (0.72–1.87) 1.09 (0.94–1.27)
SES
 Poorest 1 1 1 1 1 1
 Poor 0.90 (0.67–1.19) 0.83 (0.67–1.03) 1.10 (0.72–1.65) 0.92 (0.61–1.35) 1.08 (0.70–1.63) 0.92 (0.80–1.06)
 Least poor 0.96 (0.73–1.26) 0.78 (0.63–0.98) 0.94 (0.62–1.44) 0.86 (0.59–1.25) 1.05 (0.68–1.61) 0.88 (0.76–1.03)
Period
 2007–2010 1 1 1 1 1 1
 2011–2015 0.58 (0.45–0.72) 0.56 (0.47–0.67) 0.72 (0.51–1.03) 0.64 (0.47–0.88) 0.68 (0.47–0.96) 0.56 (0.50–0.63)
Elevation
 1147–1243 1 1 1 1 1 1
 1244–1293 1.05 (0.75–1.46) 1.17 (0.85–1.61) 0.94 (0.54–1.60) 1.05 (0.62–1.77) 0.89 (0.50–1.55) 1.08 (0.87–1.34)
 1294–1327 0.47 (0.31–0.70) 1.10 (0.78–1.58) 1.02 (0.56–1.79) 0.79 (0.45–1.41) 1.00 (0.55–1.75) 0.84 (0.67–1.08)
 1328–1365 0.65 (0.43–0.98) 1.00 (0.70–1.47) 0.99 (0.51–1.88) 0.89 (0.49–1.65) 1.15 (0.60–2.14) 0.88 (0.68–1.13)
 > 1365 0.36 (0.21–0.58) 0.88 (0.58–1.34) 1.39 (0.69–2.76) 0.58 (0.28–1.16) 1.29 (0.65–2.50) 0.71 (0.52–0.94)
Spatial variance 0.53 (0.17–2.43) 0.75 (0.21–4.40) 0.49 (0.16–2.43) 0.78 (0.18–4.08) 0.64 (0.22–2.65) 0.95 (0.21–7.62)
Ranged 22.40 (8.42–92.52) 16.00 (8.22–74.12) 28.82 (8.47–91.99) 15.40 (8.21–86.65) 16.87 (8.32–75.36) 15.27 (8.19–78.32)
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who were severely ill may have gone to the hospital or 
succumbed to the disease prior to the time of the sur-
vey. Furthermore, an increase or decrease in mortal-
ity could be also due to other unmeasured factors that 
are unrelated to parasite prevalence; an example was 
shown by the influence of political instability on mor-
tality in the year 2008 in Kisumu [29] that resulted in 
massive disruption of health delivery.
The lack of association between PP or clinical malaria 
and mortality in the 15–49 age groups may be an indi-
cator of misclassification of malaria as a cause of death 
by verbal autopsy. This weakness of verbal autopsy in 
identifying malaria as a cause of death among adults 
[30] could result in fewer deaths being classified as 
malaria than there really are in the population. Evidence 
suggests that people with HIV have more frequent epi-
sodes of symptomatic malaria [31] and that malaria 
increases HIV plasma viral load and decreases CD4+ 
T cells [32]. Therefore, an alternative explanation could 
be that malaria specific mortality among adults may be 
classified by verbal autopsy as HIV/AIDS-related rather 
than malaria related.
The estimated effects of PP and clinical malaria 
were higher for malaria-specific mortality compared 
to all-cause. Furthermore, clinical malaria was a bet-
ter predictor of mortality than PP. In fact, some of the 
asymptomatic infections may neither lead to severe 
disease nor death and therefore prevalence of clini-
cal malaria is a better indicator for monitoring the dis-
ease burden at the population level. The stronger effect 
of clinical malaria and PP on malaria-specific mortal-
ity compared to all-cause mortality indicates that an 
increase in malaria transmission measures results in 
more malaria deaths which in turn inflate overall mor-
tality. The stronger effect of prevalence on malaria spe-
cific mortality is because there is a clear biological cause 
and effect [33] and malaria infection can and does lead 
to mortality, however, the relationship between preva-
lence and all-cause mortality is diluted by other causes of 
mortality.
From these findings, it is worth noting that preva-
lence as a measure of transmission shows more stabil-
ity in determining mortality over longer periods of time 
(4–5  years) compared to annual measures. Comparing 
estimates of the relation between mortality and malaria 
transmission measured by prevalence (of parasitaemia 
and confirmed malaria) in the current study, incidence 
measured as slide positivity rate (SPR) [10] and the log of 
EIR from capture better the relationship between malaria 
transmission and mortality (Table 4). Confirmed malaria 
prevalence averaged over 4–5  years is likely to be more 
stable in areas of high transmission and therefore a use-
ful measure of transmission over a long period while 
incidence and EIR capture the malaria-mortality relation-
ship better over shorter periods [10, 34]. These differ-
ences could be due to the fact that PP one-off estimates 
can be misleading indicators of long-term transmission 
potential, since they vary markedly with season [35]. 
These short-term fluctuation would then make it harder 
to associate yearly PP measures with mortality occurring 
all year round; suggesting that population based preva-
lence surveys do represent long term transmissions as 
opposed to short term changes.
Higher socioeconomic status, shorter distance to 
health facilities and increasing altitude are known 
protective factors that were statistically important for 
both, all-cause and malaria-specific mortality. Indi-
viduals at a higher social status are more likely to live 
in well-constructed houses that offer better protection 
against endophagic/endophilic malaria vectors that 
transmit malaria in sub-Saharan Africa, afford better 
nutrition and pay for superior treatment [36]. Increas-
ing elevation is associated with lower temperatures 
which increase the development time of both vector 
and parasite [37], resulting in lower transmission. Simi-
larly, it has been shown that distance to health facilities 
influences mortality [38].
Lack of association between net use and mortality 
across ages except for yearly data among the elderly 
could be due to data aggregation at village level which 
diminished the expected individual level protection 
associated with net use reported in earlier studies dur-
ing the 90′s and early 2000′s in the same region [34, 39]. 
This change from earlier years could have been due to a 
number of factors among them ITN’s having achieved 
maximum benefits, compromised effectiveness due 
to misuse/pyrethroid resistance or other unmeasured 
factors which countered their protective effect (Hamel 
et  al. pers.commun.). The diminished effect of net use 
might also be due to use of self-reported net use infor-
mation which could lead to bias as it does not meas-
ure constant use. The negative effect of net use on 
malaria-specific mortality among the elderly, a group 
that has not been well researched in malaria cannot be 
explained adequately, and requires further investiga-
tion. However, it could be hypothesized that since mor-
tality is generally high in this age-group, at the same 
time society considers them vulnerable, issuance and 
use of ITNs could be higher and hence their protective 
effect is masked.
There are inherent limitations in survey data and in 
estimating malaria mortality using verbal autopsy that 
could influence the study results. First, the surveys were 
conducted in specific months (i.e. in April, just before 
the rains (or just as they were starting) or June/July 
after the rains were ending.); therefore, the prevalence 
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estimates of may be biased by unexpected changes in 
climatic and environmental factors in other. Use of ver-
bal autopsy as a tool for determining cause of death has 
been criticized [30], even though recent improvements 
in the InterVA coding have been said to reduce classifi-
cation errors, especially at population level [40]. Despite 
these limitations, the 9-year data in the study have been 
collected consistently in the same area using rigorous 
data collection methods and strict quality control meas-
ures. These data are thus unique in studying the relation 
between malaria prevalence and mortality across all 
groups in this population within a high endemic area.
Conclusion
From yearly cross-sectional malaria prevalence surveys, 
the study showed that; (i) Clinical malaria at population 
level best captures the association with mortality among 
children aged 1–4  years and 5–14  year olds. It can also 
be used as a marker of malaria mortality in the general 
population. (ii) Prevalence as a measure of transmission 
is more stable over longer periods of time (4 to 5 years) 
compared to incidence or EIR which better capture the 
malaria-mortality relationship on a yearly basis. How-
ever, its lower size effect compared to clinical malaria 
may underestimate malaria deaths. Analyses of data from 
other HDSS sites or similar platforms with differing levels 
of malaria endemicity different socio-economic status, or 
different access to effective anti-malarial drugs would 
be useful in understanding the contribution of parasite 
prevalence to mortality across age groups.
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